Asia Fresh News

Asia Fresh Stories

Archive for July 30th, 2014

Frost & Sullivan Applauds Gamma Medica for Improving the Quality and Efficiency of Breast Cancer Diagnosis with its Unique LumaGEM MBI System

leave a comment »

-Gamma Medica meets the global demands of breast imaging by providing high sensitivity and specificity

MOUNTAIN VIEW, Calif./PRNewswire/ — Based on its recent analysis of the breast imaging systems market, Frost & Sullivan recognizes Gamma Medica with the 2014 Global Frost & Sullivan Award for Product Leadership. Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system provides breast images through the digital direct conversion of photons in gamma rays into electronic charges that form the image. It equips clinicians with MBI technology to detect tumors in women with dense breast tissue and plan treatment measures as early as possible.

Gamma Medica has demonstrated its dedication to improving the standard of care for breast cancer patients by offering the advanced cadmium zinc telluride (CZT) solid state detector technology in its LumaGEM MBI system.

“While other adjunct technologies such as ultrasound and magnetic resonance imaging are available, either their inability to locate microcalcifications or their low specificity can throw up inconclusive results,” said Frost & Sullivan Research Analyst Raghuraman Madanagopal. “On the other hand, Gamma Medica’s LumaGEM MBI system can efficiently locate lesions as small as 5 millimeters in size and help identify the tumor as benign or cancerous.”

The LumaGEM MBI system has the highest negative predictive value (NPV) among adjunct technologies used for breast cancer diagnosis, making it one of the most reliable systems for this purpose. It also has a high intrinsic spatial resolution of 1.6 millimeters and provides high-quality images that enable clinicians to locate tumors, measure them, and understand their functional and metabolic activities.

While there are shortcomings with every adjunct technology that is used for breast cancer diagnosis, the LumaGEM MBI system, with a high sensitivity of 91 percent and a high specificity of 93 percent, offers customers unprecedented precision. The LumaGEM MBI system utilizes a dual-head technology that effectively locates cancers in cases that previously were either inconclusive or determined to be negative on mammography images.

As the imaging is done on the mediolateral oblique and the cranio-caudal planes, it is easily comparable to mammography images. The scanning procedure in the LumaGEM MBI system uses minimal compression and is performed with the subject in a seated position.

“The LumaGEM MBI system has a small-sized gamma camera that is located closer to the breasts,” notedRaghuraman Madanagopal. “As a result, the amount of radiation required for obtaining images is less than one-third of the amount used in most breast-specific gamma imaging modalities. Frost & Sullivan research shows that this ability provides Gamma Medica a technological advantage over its competitors.”

“Gamma Medica is committed to making MBI a more widely used tool in the battle against breast cancer,” said Jim Calandra, president and chief executive officer of Gamma Medica. “We are pleased to have been recognized by Frost & Sullivan for our efforts and are excited to drive breast cancer diagnosis technology forward with highly advanced, patient-friendly and cost-effective tools.”

Gamma Medica has made its products commercially available throughout the United States, as well as in certain parts of Europe, and hopes to expand to other regions of the world. By utilizing innovative technologies and effective growth strategies, Gamma Medica has ensured a superior competitive position for itself in the global breast imaging systems market.

Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Gamma Medica

Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM® Digital MBI system, the first commercially available, FDA-cleared planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging. For more information, visit www.gammamedica.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

Sang Lee
VP of Sales and Marketing
P: 603.952.4441
E: media@gammamedica.com

Source: Frost & Sullivan

Written by asiafreshnews

July 30, 2014 at 6:30 pm

Forget The Dongle – Givex Introduces New Vexilor POS Tablets With Built-In Card Readers

leave a comment »

TORONTO /PRNewswire/ — The next generation of Vexilor V10 tablets have launched with an integrated magnetic stripe reader (MSR) and unique Plug and Play capabilities.

Vexilor V10 Gen 2 shown here with stand mount and optional customer facing tablet.
Vexilor V10 Gen 2 shown here with stand mount and optional customer facing tablet.

Photo – http://photos.prnewswire.com/prnh/20140718/128655

Researched and designed with the help of business partners, Vexilor is an agile POS that is more than an iPad App. Vexilor is an enterprise level POS solution using tablets that are not only designed to look sleek and enhance any business environment, but are also custom manufactured strong enough to withstand rough handling and a range of indoor and outdoor business settings.

Enterprise level businesses used to be held back by the expenses associated with purchasing, installing, and maintaining legacy POS systems. For less than the costs businesses were traditionally spending on three or four legacy POS stations, Vexilor V10 tablets can create five or six of the same. Businesses have been able to speed up cash-out times, decrease table-turn times, and increase operational efficiencies across multiple industries.

The V10 Gen 2 Vexilor tablets build upon the well-received V10 Gen 1 tablets and are designed to meet the growing demands of enterprise businesses. A built-in magnetic stripe card reader (not just a dongle) for processing transactions involving Givex gift or loyalty cards and coupon redemptions is one of the enhanced business features of the Vexilor V10 Gen 2 tablets.

The V10 Gen 2 tablets can easily be mounted to serve as workstations or customer facings screens. Powered over Ethernet (POE), they don’t rely on secondary power cords or bulky wall warts, it’s as simple as plugging in one cable and businesses are ready to go. More stable than WiFi, Ethernet gives operators peace of mind when running their businesses, no more worrying about splitters, chargers, or unstable internet connections.

“The enhancements to the Vexilor V10 Gen 2 tablets are a result of Givex working closely with our clients to deeply understand their business needs and demands of their respective industries, and working to always evolve with those needs and demands” says Graham Campbell, SVP Product Development at Givex. He furthers “the Gen 2 Vexilor V10 tablets speak to Vexilor’s agile development, and our commitment to help businesses unleash their full potential.”

Vexilor is being used by businesses in USA, Canada, UK, Australia, Hong Kong, and mainland China.

About Givex

Givex is a technology company offering clients a global reach with cost-effective gift card, omni-channel loyalty, analytics, stored value tickets, and cloud-based POS systems. Our core distinction is taking on the tough task of managing all aspects of the transaction to ensure companies can deliver maximum customer satisfaction. Givex products and services give you insight into your data to enable you to better drive sales growth, customer relationship management and enterprise resource planning.

Website: http://www.givex.com

For more information or media inquiries, please contact

Bryan Wang
Director of Marketing
Givex
Phone: +1.416.350.9660 x 309
Toll free: 1.877.478.7733
Fax: +1.416.350.9661
Email: bryan.wang@givex.com

Source: Givex

Written by asiafreshnews

July 30, 2014 at 6:11 pm

Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma

leave a comment »

DARMSTADT, Germany  /PRNewswire/ —

  • First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC)
  • mMCC is a rare and aggressive skin cancer lacking effective treatments
  • MSB0010718C is also currently being explored in a seven cohort Phase I clinical trial for the treatment of solid tumors that aims to recruit 590 patients

Merck Serono, the biopharmaceutical division of Merck, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). This multicenter, single-arm, open-label study is being conducted in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin tumor,[1],[2] who have previously received one line of chemotherapy. It is expected to recruit 84 patients across Asia Pacific, Australia, Europe and North America. The primary endpoint of the study is overall response.

The PD-L1/PD-1 pathway is implicated as a major mechanism by which tumors evade elimination by the immune system.[3] The PD-L1 molecule is expressed in many cancer types, including mMCC.[3],[4]MSB0010718C, which blocks the interaction of PD-L1 with its receptor PD-1, may have the potential to restore effective anti-tumor T-cell responses and thereby to inhibit tumor growth.

Immune mechanisms are implicated in the pathogenesis of MCC, with an increased risk observed in immunosuppressed individuals.[5] MCC also is associated with the presence of the Merkel cell polyomavirus, which may have a role in tumor formation.[6] Globally, the incidence of MCC is increasing, and outcomes for patients with this disease are poor.[1],[2] Therefore, new treatment approaches are required to improve the outcome of patients with this type of cancer.

“We believe that modulating the immune system by targeting PD-L1 represents a promising new approach in the treatment of this aggressive cancer, especially considering that many of the predisposing factors for mMCC seem to be related to functional disruptions of the immune system,” said Helen Sabzevari, Senior Vice President of Immuno-Oncology at Merck Serono. “Our anti-PD-L1 compound may present a potential new approach for the treatment of mMCC patients. The initiation of this Phase II study is an important milestone, as we endeavor to help those suffering from mMCC, a devastating disease with significant unmet need.”

In addition to this new study in mMCC, MSB0010718C is currently being explored in a Phase I clinical trial for the treatment of solid tumors. The study aims to recruit 590 patients and has enrolled 422 patients to date. On June 1, 2014, Merck Serono presented initial data from this dose escalation study in solid tumors at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago.[7] This study is currently recruiting patients into expansion cohorts in seven cancer types: castrate-resistant prostate cancer, colorectal cancer, gastric/gastroesophageal cancer, melanoma, metastatic breast cancer, non-small cell lung cancer and ovarian cancer.

References

  1. Hughes MP, et al. Curr Dermatol Rep 2014;3:46-53.
  2. Kaae J, et al. J Natl Cancer Inst 2010;102(11):793-801.
  3. Lipson EJ, et al. Cancer Immunol Res 2013;1(1):54-63.
  4. McDermott DF and Atkins MB. Cancer Med 2013; 2(5):662-73.
  5. Bhatia S, et al. Curr Oncol Rep 2011;13(6):488-97.
  6. Feng H, et al. Science 2008;319(5866):1096-100.
  7. Heery CR, et al. J Clin Oncol 2014;32:5(Suppl.) Abstract No. 3064.

About MSB0010718C

MSB0010718C is an investigational fully human IgG1 monoclonal antibody that binds to the PD-L1 (programmed death-ligand 1) protein, which is present at high levels in many cancer types. By competitively blocking the interaction with PD-1 receptors, it is believed that MSB0010718C thereby restores anti-tumor T-cell responses.

About Merkel cell carcinoma (MCC)

MCC is a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings. MCC, which is also known as neuroendocrine carcinoma of the skin or trabecular cancer, often starts in those areas of skin that are most often exposed to the sun, including the head and neck, arms, legs, and trunk. Risk factors for MCC include sun exposure and having a weak immune system (i.e., solid-organ transplant recipients, people with HIV/AIDS and people with other cancers, such as chronic lymphocytic leukemia, are at higher risk). Caucasian males over age 50 are at increased risk.

MCC tends to metastasize at an early stage, spreading initially to nearby lymph nodes, and then potentially to more distant areas in the body, including other lymph nodes or areas of skin, lungs, brain, bones, or other organs.

Current treatment options for MCC include surgery, radiation and chemotherapy. Treatment for metastatic or Stage IV MCC is generally palliative.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit http://www.merckserono.com.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.

Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.

Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions areCanada and the United States, where the company is known as EMD.

Source: Merck Serono

Written by asiafreshnews

July 30, 2014 at 4:27 pm

Posted in Uncategorized

Neuberger Berman Appoints Former KKR Executive Clifford Chiu As Senior Adviser For Asia

leave a comment »

NEW YORK and HONG KONG /PRNewswire/ — Neuberger Berman, one of the world’s leading employee-controlled investment managers, is pleased to announce the appointment of Clifford Chiu, former partner member at KKR & Co., as Senior Adviser to Neuberger Berman Asia, effective immediately.

Logo – http://photos.prnewswire.com/prnh/20121010/MM90850LOGO

Mr. Chiu will work across the Asia Pacific region to help Neuberger Berman continue to build its Asian client base. Mr. Chiu recently retired from KKR where, as the partner overseeing the firm’s client business in Asia including Japan, he and his team raised close to US$15 billion in commitments from institutional investors in Greater China, Korea,Japan, Southeast Asia and Australia, for the various KKR private equity funds.

“We are delighted to welcome Clifford to our team in Asia and learn from his vast insights as we continue to expand our presence in this region,” said Nick Hoar, managing director and head of Asia Pacific for Neuberger Berman.

In addition to his leadership of KKR in Asia including Japan, Mr. Chiu served as a managing director responsible for the Asian institutional business with JP Morgan in Hong Kong andTokyo from 2002-2007, and earlier as managing director and head of Hong Konginvestment banking and co-head of Japan investment banking with Citigroup/Salomon Smith Barney in Hong Kong, Tokyo and New York.

Mr. Chiu currently serves as a director of Hsin Chong Construction Group and Cambium Learning Group, and holds Hong Kong government appointments as a board/committee member at the Financial Services Development Council (FSDC), Hospital Authority’s (HA) Tsuen Kwan O Hospital, and West Kowloon Cultural District Authority. Additionally, he serves as a director of the global advisory boards at the University of Chicago Booth School of Business and the University of Pennsylvania’s Weingarten Learning Resources Center. Mr. Chiu holds a Bachelor of Science in Economics degree from the University of Pennsylvania, Wharton School of Business, and his Masters of Business Administration from the University of Chicago Booth School of Business.

Neuberger Berman Asia employs more than 120 people and manages assets on behalf of some of the region’s leading sovereign wealth funds, pension funds, insurance companies, private and retail banks.

Neuberger Berman

Neuberger Berman is a 75-year-old private, independent, employee-controlled investment manager. The firm manages equities, fixed income, private equity and hedge fund portfolios for institutions and advisors worldwide. With offices in 17 countries, Neuberger Berman’s team is more than 2,000 professionals and the company was named by Pensions & Investments as a 2013 Best Place to Work in Money Management. Tenured, stable and long-term in focus, the firm fosters an investment culture of fundamental research and independent thinking. It manages $257 billion in client assets as of June 30, 2014. For more information, please visit our website at www.nb.com.

Media Contact:
Alex Samuelson, 212.476.5392, Alexander.Samuelson@NB.com
Asia, David Bloomfield, 852 3664 8838, David.Bloomfield@NB.com

Written by asiafreshnews

July 30, 2014 at 4:15 pm

Posted in Uncategorized

ATP Introduces advancedMLC (aMLC) Technology at Flash Memory Summit

leave a comment »

-aMLC provides Best Drive-Write Per Day Over Cost (DWPD/Cost) Compared to SLC/eMLC/MLC
TAIPEI, July 29, 2014 /PRNewswire/ — ATP, the leading manufacturer of embedded Flash and ruggedized SSD and DRAM modules, introduces its latest technology, advancedMLC, also known as “aMLC”. Developed by ATP, aMLC is an advanced firmware technology uniquely implemented onto ATP’s NAND Flash products to vastly improve the endurance and performance of these storage devices while using mainstream MLC NAND to provide the best cost effective solution for any read/write intensive applications. ATP will showcase this technology and related products at the Flash Memory Summit 2014 from August 5 to 7 at the Santa Clara Convention Center, booth# 516.

The Benchmarking of MLC, eMLC and aMLC Endurance and performance are the two critical factors for a NAND Flash storage device to meet the demanding industrial operating requirements. However, system and product designers often have to make compromises to fulfill the necessary criteria due to the inherent high cost of SLC NAND Flash components. To address this requirement, ATP introduces aMLC technology by implementing its unique firmware to manipulate four states of MLC into two states, which dramatically widens the disturbance margins among NAND Flash cells. In addition, aMLC can provide more than 13x (40K P/E) higher endurance than traditional MLC NAND, with write performance close to SLC. As such, aMLC is best suited for any write intensive application requiring competitive Drive-Write-Per-Day over Cost (DWPD/Cost).

To learn more about ATP aMLC technology and its latest NAND Flash reliability solutions, ATP will deliver a presentation session on “Innovative Reliability NAND Flash Solution Selection and Configuration”, on Thursday, August 7th, from 2:40-3:55PM at the Flash Memory Summit conference.

The ATP initial aMLC product lines include mSATA, SlimSATA, and 2.5″ SSD, with others to follow. For further details contact your local ATP representatives, or email info@atpinc.com

Media Contact:

Ming-Chia Tsai
Phone Number: +886-2-2659-6368 #217
Email: mingchiatsai@tw.atpinc.com

Photo – http://photos.prnasia.com/prnh/20140725/8521404212

About ATP

ATP is a leading manufacturer of high performance, high quality and durable NAND flash memory solutions as well as DRAM memory modules. With over twenty years of experience in the design, manufacturing and support of memory products, ATP continues to focus on business critical applications such as industrial automation, telecom, medical and enterprise computing where high levels of technical support, performance consistency and wide operating temperature ranges are required. For more information on ATP aMLC products, please contact us at Info@atpinc.com.

Source: ATP Electronics Taiwan

Written by asiafreshnews

July 30, 2014 at 4:06 pm

Posted in Uncategorized

OANDA Revolutionizes Mobile Trading with fxTrade Mobile 4.0

leave a comment »

Global forex broker redefines retail mobile trading and maintains leadership position with industry-first features

SINGAPORE, July 24, 2014 /PRNewswire/ — OANDA, a global provider of innovative foreign exchange and CFD trading services, is pleased to announce the first phase of its next-generation fxTrade Mobile trading application. Beginning with new, industry-first features to its proprietary application for the Apple iPad, OANDA is moving away from a “one-size-fits-all” approach to mobile trading.

Available now for free download in the App Store, OANDA’s fxTrade Mobile 4.0 for iPad features unlimited charts, the ability for individual traders to arrange charts however they wish, and the ability to view charts in full-screen mode.

“We’re redefining the way investors are trading on mobile, moving toward customization based on each trader’s experience and trading strategies. We started with the iPad, as it’s the tablet with the highest market penetration and the most screen real estate,” said Reuben Piryatinsky, Mobile Product Manager, OANDA Corporation. “We’re confident this new approach to trading will help us maintain our industry-leading position in the mobile space.”

OANDA’s mobile team will continue to release more customizable features, specific to individual trading styles, in the coming months. New elements in fxTrade Mobile will add to its existing advanced charting functionality with multiple chart types and more than 40 technical analysis indicators, overlays, and drawing capabilities, streaming news feeds, and push notifications for limit orders, stop-loss and take-profit actions, margin notifications, and price alerts.

“We were the first broker to release a tablet trading app and so much has changed in four years. At the time, our goal was to match the desktop feature set but we’ve already eclipsed that and have more rich features available for mobile,” said Trevor Young, Vice President of Product Management, OANDA Corporation. “We are also seeing increased volumes coming through mobile: in 2010, it accounted for two or three percent of total volume and today it is closer to 20 percent.”

Today, more than 50 percent of OANDA’s clients log-in to their accounts daily via fxTrade Mobile. Like OANDA’s MetaTrader 4 mobile applications for iPhone and Android smartphones and tablets, and OANDA’s Currency Converter for iPhone, iPad, iPod touch, and Android devices, fxTrade Mobile is available to download for free.

For more information, please visit http://www.oanda.sg. You can follow OANDA on Twitter, Facebook, orYouTube.

For more information, please contact:

The Hoffman Agency for OANDA Asia Pacific
Adele Soh
Direct: +65-6361-0250
Email: OANDASG@hoffman.com
www.hoffman.com

About OANDA

OANDA transformed the business of foreign exchange through an innovative approach to forex trading. The company’s industry leading online trading platform, fxTrade, introduced a number of firsts to the marketplace, including immediate execution; instant settlement on trades; trades of any size between one unit and 10 million units; and interest calculated by the second. The company’s many awards attest to the power and flexibility of its trading platform. In 2013, OANDA was honoured with nearly a dozen awards, including Best Trade Execution Provider, Best Retail Trading Platform and Best Mobile Trading Platform by International Finance Magazine; as well as Best Value for Money by Investment Trends in each of the U.S., UK, and Asia Pacific markets.

OANDA was also amongst the first online providers of comprehensive currency exchange information, and today the company’s OANDA Rate® data provides benchmark rates for corporations, auditing firms, and global banks.

OANDA has eight offices worldwide, in Toronto, Chicago, New York, Boston, London, Singapore, Tokyo, andSydney. OANDA is fully regulated by the U.S. Commodity Futures Trading Commission (CFTC), the U.S. National Futures Association (NFA), the Monetary Authority of Singapore (MAS), the Investment Industry Regulatory Organization of Canada (IIROC), the UK Financial Conduct Authority (FCA), the Japanese Financial Services Agency (FSA), and the Australian Securities and Investments Commission (ASIC).

About OANDA Asia Pacific

This information is made available to you by OANDA Asia Pacific Pte Ltd. OANDA Asia Pacific Pte Ltd holds a Capital Markets Services Licence issued by the Monetary Authority of Singapore and is also licensed by the International Enterprise Singapore. Co Reg No. 200704926K. Trading in leveraged over-the-counter contracts for foreign currency, precious metals, and CFDs carries a high level of risk and may not be suitable for all investors. You should never put at risk any amount that you cannot afford to lose. More details under:http://www.oanda.sg/legal/risk-warning .

© 1996 – 2014 OANDA Corporation. All rights reserved. All Registered Trade Marks used in this set of material, whether marked as Trade Marks or not marked, are declared to belong to their respective owner(s). OANDA Corporation owns Trade Marks of all its “FX” products.

The information on this material is not directed at residents of the United States, nor is it intended for distribution to, or use by, any person in any jurisdiction, where such distribution or use is contrary to local laws or regulations.

Source: OANDA

Written by asiafreshnews

July 30, 2014 at 3:58 pm

Posted in All releases

Apex Continues Fighting Against Patents to Free Up Competition

leave a comment »

TAIPEI, July 29, 2014 /PRNewswire/ — Apex Medical Corporation (Apex, TWSE: 4106), a leading player in the Respiratory Therapy and Pressure Area Care sectors, announces that it is appealing the judgment of the Regional Court of Munich in Germany that found the headgear of certain mask models infringe a ResMed patent. Apex notes that it has initiated invalidity challenges against various ResMed patents in major countries. Apex further reiterates its continuous efforts in counterattacking against trivial and junk patents.

ResMed filed the lawsuit with the Regional Court of Munich in November 2013, a few months after Apex successfully terminated patent litigation brought by ResMed in the US. The patent at issue is relating to fastening portion such as Velcro used in the headgear. The Regional Court of Munich held that Apex’s Wizard 210 and Wizard 220 headgears were covered by one European patent of ResMed. However, as early as December 2013, Apex has challenged the validity of the same ResMed patent before the European Patent Office. Apex thus will appeal the judgment entered by the Regional Court.

Apex notes that the judgment is limited to headgears of specific masks distributed in Germany and does not cover masks or any other respiratory therapy products. Also, Apex’s new headgear design is ready to be offered to the customers. The Regional Court’s judgment therefore has limited effect on Apex’s global operation.

In addition, earlier this year Apex has initiated patent invalidity challenges against ResMed’s other German and European patents that ResMed asserted in separate proceedings. Meanwhile, based on the evidence submitted by Apex, the patent agencies in the United States, Japan, and China are conducting independent review on the validity of several ResMed patents.

The Company reiterates its belief that invalid or junk patents not only harm fair competition but also obstruct patients’ access to quality products. Apex thus will continue fighting against invalid or junk patents to ensure freedom to market and fair competition.

Apex stresses its goal of serving patients suffering from sleeping disorders with quality, effective as well as cost-saving CPAP products, and affirms its devotion to innovation and its commitment to the customers.

About Apex

Apex Medical is a leading manufacturer of its own brand of Respiratory Therapy products and distributes through an established network of international subsidiaries and partners in Europe, the United States, Asia and other international markets. Apex specializes in product development, engineering and marketing products with a dedicated and innovative team of industry professionals. Apex aims to be a global leader in the provision of high quality healthcare products, delivering tested, trialed and clinically evaluated devices while ensuring that its own technology and intellectual property meet the demands of the Respiratory Therapy market.

Contact:

Jack Hsu
Vice President
Apex Medical
Tel: +886-2-22685568
Jack.hsu@apexmedical.com.tw

Written by asiafreshnews

July 30, 2014 at 3:42 pm

Posted in Uncategorized

CNH Industrial Inaugurates New Agricultural Equipment Manufacturing Complex in China

leave a comment »

— CNH Industrial celebrated today the opening of its new manufacturing complex in Harbin, in Heilongjiang Province. It is the largest agricultural equipment production plant in Northeast China and will produce a complete line of products under its Case IH and New Holland Agriculture brands to support the Country’s agricultural needs, and the full cycle of corn, wheat, soybean and hay production.

HARBIN, China /PRNewswire/ — CNH Industrial inaugurated its new manufacturing complex built in the area of its previous assembly plant in Heilongjiang Province, China. The biggest agricultural equipment manufacturing facility in Northeast China, the complex extends over a total area of 400,000 square meters of which 116,000 are covered. The vertically integrated manufacturing complex features the latest technology in fabrication and two state-of-the-art painting facilities. Automated Guided Vehicles (AGVs) are utilized for the assembly and testing of the finished products to guarantee the highest quality standards. Within the complex is a Customer Center with a spacious showroom to support dealers. In addition a Research & Development Center with a dedicated outdoor test track opened in September 2013 and houses the engineering team tasked with designing components and adaptations for the domestic market. These facilities are complemented by the nearby spare parts depot and Training Center.

The new manufacturing plant will produce a wide range of product lines: planters, tractors, combine harvesters and corn pickers with their headers, balers and hay tools. Its production will include a complete line of equipment for the mechanization of the full cycle of corn, wheat, soybean and hay production. Among its products will be the legendary Case IH Axial-Flow combine range adapted for local conditions and Case IH corn pickers entirely developed for the Chinese market, as well as the award winning New Holland T6000 and T7000 tractor ranges and BC5000 balers.

Richard Tobin, CEO of CNH Industrial, commented, “CNH Industrial has a strong and long standing relationship with China. Through our agricultural equipment brands we have been present in this country for more than 100 years, supporting the mechanization of its agriculture and gaining leading positions in the market for high horsepower tractors, large combine harvesters, cotton pickers, sugar cane harvesters and balers. Our new manufacturing complex here in Harbin represents an investment of over USD $100 Million and its inauguration marks an important milestone that confirms our commitment to the development of Chinese agriculture.”

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

For more information contact:

Asia Pacific Press Office
Tel: +39 011 008 6346
Email: media.apac@cnhind.com

Source: CNH Industrial

Written by asiafreshnews

July 30, 2014 at 2:15 pm

Posted in Environment, Metalwork

Fusionex Wins Prestigious Award for Its Innovation at Microsoft’s Premier Worldwide Partner Conference (WPC)

leave a comment »

WASHINGTON, July 30, 2014 /PRNewswire/ — Today, Fusionex announced that it has won the coveted award at the 2014 Worldwide Partner Conference in Washington DC, cementing its status as a top Microsoft Partner. This marks the third consecutive year that Fusionex has won a prestigious award at the Microsoft Worldwide Partner Conference. The company was honored among a global field of top Microsoft Corp partners at Microsoft’s Premier Worldwide Partner Conference in Washington DC, for demonstrating excellence in innovation based on Microsoft’s platform.

A WINNING PARTNERSHIP: LEFT: Ivan Teh, Fusionex Managing Director, with Satya Nadella, CEO of Microsoft during the private Microsoft Awards Reception, where the world's top Microsoft partners were invited to an exclusive, invitation-only event in Washington DC, United States; RIGHT: Ivan Teh with Phil Sorgen, Corporate Vice President, Microsoft Worldwide Partner Group, at the prestigious award ceremony during the 2014 Microsoft Worldwide Partner Conference held in Washington DC, United States
A WINNING PARTNERSHIP: LEFT: Ivan Teh, Fusionex Managing Director, with Satya Nadella, CEO of Microsoft during the private Microsoft Awards Reception, where the world’s top Microsoft partners were invited to an exclusive, invitation-only event in Washington DC, United States; RIGHT: Ivan Teh with Phil Sorgen, Corporate Vice President, Microsoft Worldwide Partner Group, at the prestigious award ceremony during the 2014 Microsoft Worldwide Partner Conference held in Washington DC, United States

“Winning this prestigious award at the WPC for 3 years running is an amazing feat. It is a great testimony towards the pedigree and continuous, razor-sharp focus of our team that offers no compromise in pursuit towards delivering the most innovative products and solutions centered around business intelligence, analytics, data management, Big Data in an exciting cloud-first, mobile-first, yet hybrid world,” says Ivan Teh – Fusionex Managing Director. “I am honored to receive this award from Microsoft, which I’d like to dedicate to the Fusionex team for their tireless efforts, and in pushing forward to be the best in what we do.”

The Microsoft Worldwide Partner Awards honor partners that have demonstrated business excellence in delivering Microsoft solutions to multiple customers over the past year. This award recognizes Fusionex as succeeding in the showcase of innovation and business impact, driving customer satisfaction and winning new customers. Inadvertently, Fusionex’s provision of award-winning solutions that brings high business value, impact and useful insights to customers played a key role towards its rare 3-year winning streak.

Awards were presented in multiple categories, with winners chosen from a set of more than 2,800 entrants from 117 different countries worldwide. Fusionex was recognized for providing outstanding software and solutions to its customers.

“The 2014 Partner of the Year Award winners and finalists honor our top partners that solve complex business challenges by providing innovative solutions to our mutual customers. Microsoft’s success as a company depends on great partners, and Fusionex is a shining example of the kind of innovation our partner ecosystem drives year after year,” said Phil Sorgen, corporate vice president, Worldwide Partner Group, Microsoft Corp. “We are honored to again recognize Fusionex as one of Microsoft’s Top Partners, and we applaud Fusionex’s dedication in providing innovative solutions that drive great results for our mutual customers.”

About Fusionex

Fusionex is a multi-award winning, premier IT group listed on the London Stock Exchange, that specializes in Business Intelligence, Analytics & Big Data. Fusionex focuses on helping its customers manage, understand as well as derive value and insight from data.

Fusionex’s products and solutions are ideal for companies seeking superior level yet user-friendly solutions including that of business intelligence (BI) and Analytics including social analytics, as well as data management & large databases (Big Data & Cloud based solutions).

To learn more about Fusionex, visit http://www.fusionex-international.com.

Product or service names mentioned herein may be the trademarks of their respective owners.

Photo – http://photos.prnasia.com/prnh/20140726/8521404236

Source: Fusionex

Written by asiafreshnews

July 30, 2014 at 1:25 pm

Posted in Uncategorized

Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market

leave a comment »

— MobileHelp has consistently delivered strong value with its simple interface and superior emergency referral

MOUNTAIN VIEW, California /PRNewswire/ — Based on its recent analysis of the personal emergency response systems (PERS) market, Frost & Sullivan recognizes MobileHelp with the 2014 North America Frost & Sullivan Award for Price Performance Value Leadership. MobileHelp’s leadership in flexibility across in-home and mobile usage directly captures expectations for tech progression in personal emergency response, and exemplifies key demands of US consumers for these solutions.

MobileHelp is at the forefront of convenience and utility in the M-PERS market and offers a simple two product option covering the range of use cases, with a uniform cellular rate plan. MobileHelp has been active in its dedication to broader mobile medical device product goals that augment its core capabilities in emergency response. Frost & Sullivan believes that both its referral branding within facility-to-home care as well as its increasing direct-to-consumer presence will allow it to expand a cost-effective product base across the medical and monitoring spectrum over time.

Primary consumer interest factors in PERS include price, reliability, contract flexibility, and customer experience of the emergency response. MobileHelp has delivered a strong value story for buyers with its simple interface and top-class emergency referral, including robust features and services provided in system pricing for its DUO series.

MobileHelp has been a pioneer in wearable devices with its wristwatch, which greatly reduces product bulk, damage through movement or falls, and issues related to daily forgetfulness of use. Secondly, the two-step transition between the Classic and DUO product suites allows customers to seamlessly upgrade from indoor-only to mixed indoor/outdoor use, with no interruption to service. MobileHelp also focuses on return guarantees, low obligatory service commitment and easy product upgrade, making its solutions very attractive for new buyers that are seeking emergency care support without product risk.

“Mobility is a key component of shifting customer expectations in personal emergency response systems,” said Frost & Sullivan Research Analyst Daniel Ruppar. Providing systems which broaden flexibility, while offering important ease of use, service support, and other high value factors supporting solution purchase decisions are key characteristics of leadership in this important Senior focused market.

Each year, Frost & Sullivan presents this award to a company that has developed a product that offers price competitiveness, ease of use, as well as service effectiveness.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development.

About MobileHelp

MobileHelp is America’s leading provider of M-PERS (Mobile-Personal Emergency Response System) technology based in Boca Raton, Florida, and services clients in all 50 states.  MobileHelp develops and distributes market-leading products such as Cellular DUO, the first and only fully integrated medical alert system with GSM/GPS technology, which provides an in-home cellular base station and a mobile device to protect customers away from home; and the Cellular Classic system, an in-home, cellular-based Medical Alert System.  MobileHelp’s M-PERS devices are integrated with nationwide wireless voice, data and GPS technology to provide real-time medical monitoring services and location tracking for expedited personal emergency assistance. MobileHelp also offers Fall Button™, an automatic fall detection pendant and MobileHelp Connect, an innovative event notification and web portal for customers, families and caregivers. MobileHelp has built a reputation for quality and affordable solutions for personal protection and peace of mind in or away from home and is the first FDA registered mobile medical alert system provider. For sales or more information about MobileHelp, call 1-800-800-1710 or go online to www.MobileHelp.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.

Contact:

Mireya Espinoza
P: +1-210-247-3870
F: +1-210-348-1003
E: mireya.espinoza@frost.com

MobileHelp Contact:
Name: Liz Kohler
P: +1-414-828-6198
E: liz.kohler13@gmail.com

Source: Frost & Sullivan

Written by asiafreshnews

July 30, 2014 at 1:21 pm

Posted in Uncategorized